Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Jyong Biotech (Nasdaq:MENS) announced it filed its Form 20-F annual report for the fiscal year ended December 31, 2025 with the SEC on May 14, 2026.

Rhea-AI Summary

Jyong Biotech (Nasdaq:MENS) announced it filed its Form 20-F annual report for the fiscal year ended December 31, 2025 with the SEC on May 14, 2026.

The filing is available on the company’s investor relations site and the SEC website, and shareholders can request a free hard-copy with audited consolidated financial statements.

Argus May 15 session

-3.37% close to close Open Argus

Details

News Market Reaction – MENS

On May 15, the day this news came out, MENS closed 3.37% below the previous close.

Data tracked by StockTitan Argus for the May 15 session.

Key Figures

Shares outstanding: 76,027,667 ordinary shares Legal liability: USD 19.4 million Subsidy repayment: RMB 12.0 million +5 more

Shares outstanding

76,027,667 ordinary shares

As of Dec 31, 2025 per Form 20-F

Legal liability

USD 19.4 million

Taizhou investment dispute judgment per 20-F

Subsidy repayment

RMB 12.0 million

Land use and subsidy dispute per 20-F

Major holder stake

25,349,500 ordinary shares (33.34%)

Perfect Minds ownership per Schedule 13D

Stake cost

$5,760,075

Amount paid for 25,349,500 shares per Schedule 13D

Cancer incidence reduction

27.3% reduction

MCS-8 Phase II trial vs placebo

High-grade disease reduction

17.1% reduction

MCS-8 Phase II high-grade prostate cancer vs placebo

Cholesterol p-value

P=0.036

Total cholesterol reduction with MCS-8 (PCP) in Taiwan

Historical Context

5 past events · Latest: Apr 28

5 events

1. Apr 28

   Market access update

   24h Move

   +0.9%

   Outlined competitive market access strategy for botanical drugs Botreso and PCP.

2. Mar 27

   Clinical/IP update

   24h Move

   -4.0%

   Shared Phase III safety data and IP position for plant-derived drug MCS-2.

3. Feb 12

   Phase II data

   24h Move

   +0.7%

   Reported Phase II efficacy and metabolic benefits for MCS-8 plus Asian entry plans.

4. Jan 30

   Biomarker analysis

   24h Move

   -7.8%

   Released biomarker and cholesterol data for MCS-8 (PCP) supporting broader potential.

5. Dec 19

   Trading activity note

   24h Move

   -4.7%

   Addressed share price and volume moves after lock-up expiry and outlined pipeline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 20-f, securities and exchange commission, audited consolidated financial statements

3 terms

form 20-f regulatory

"announced that it filed its annual report on Form 20-F for the fiscal year"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

securities and exchange commission regulatory

"for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission"

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

audited consolidated financial statements financial

"hard copy of annual report containing the audited consolidated financial statements, free of charge"

A set of financial reports that combine a parent company and all its subsidiaries into one overall picture, examined and verified by an independent auditor. Think of it as a household budget that merges every family member’s accounts and is then checked by a neutral accountant; it gives investors a single, trustworthy view of the group’s assets, debts, income and cash flow. That independent check matters because it reduces the chance of hidden problems and helps investors compare companies on a level playing field.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

New Taipei City, Taiwan, May 15, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC") on May 14, 2026.

The annual report can be accessed on the Company's investor relations website at https://jyongir.com/ as well as the SEC's website at http://www.sec.gov. 

The Company will provide a hard copy of annual report containing the audited consolidated financial statements, free of charge, to its shareholders upon request. Requests should be directed to the Company at ir@jyongbio.com . 

About Jyong Biotech Ltd.

Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, pharmacology, toxicology, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO^®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.

For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:
Jyong Biotech Ltd.
ir@jyongbio.com

Investor Relations
WFS Investor Relations Inc.
Email: services@wfsir.com
Phone: +1 628 283 9214

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jyong Biotech (Nasdaq:MENS) file with the SEC on May 14, 2026?

Jyong Biotech filed its annual report on Form 20-F for fiscal year 2025. According to Jyong Biotech, the report covers the year ended December 31, 2025 and includes audited consolidated financial statements for investors and regulators.

Where can investors access Jyong Biotech’s 2025 Form 20-F annual report (MENS)?

Investors can access Jyong Biotech’s 2025 Form 20-F on its investor relations website and the SEC’s site. According to Jyong Biotech, the report is available at jyongir.com and on the SEC’s EDGAR platform at sec.gov.

How can Jyong Biotech (MENS) shareholders request a hard copy of the 2025 annual report?

Shareholders can request a free hard copy of Jyong Biotech’s 2025 annual report. According to Jyong Biotech, requests for the report with audited consolidated financial statements should be sent by email to the company’s investor relations address at ir@jyongbio.com.

What fiscal period does Jyong Biotech’s 2025 Form 20-F (MENS) cover?

The Form 20-F annual report covers the fiscal year ended December 31, 2025. According to Jyong Biotech, this filing provides audited consolidated financial statements and related disclosures for that full fiscal year for Nasdaq and SEC reporting compliance.

Why is Jyong Biotech’s 2025 Form 20-F filing important for MENS investors?

The 2025 Form 20-F provides audited consolidated financial statements and key company disclosures. According to Jyong Biotech, this annual report helps MENS investors review financial performance, governance information, and regulatory compliance for the year ended December 31, 2025.